INT149314

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 1.21
Pain Relevance 2.76

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (CAV2) mitochondrion organization (CAV2) intracellular (CAV2)
protein complex (CAV2) cytoplasm (CAV2) cytosol (CAV2)
Anatomy Link Frequency
lung 1
CAV2 (Homo sapiens)
Pain Link Frequency Relevance Heat
vincristine 48 100.00 Very High Very High Very High
Calcium channel 7 100.00 Very High Very High Very High
addiction 8 99.44 Very High Very High Very High
Ziconotide 6 98.72 Very High Very High Very High
Pain 19 98.68 Very High Very High Very High
Root ganglion neuron 2 95.64 Very High Very High Very High
intrathecal 3 94.88 High High
Dorsal horn neuron 2 94.60 High High
Intractable pain 1 94.28 High High
agonist 8 90.40 High High
Disease Link Frequency Relevance Heat
Pain 20 98.68 Very High Very High Very High
Lung Cancer 10 97.76 Very High Very High Very High
Ganglion Cysts 2 95.44 Very High Very High Very High
Intractable Pain 1 94.28 High High
Diabetes Mellitus 1 75.68 Quite High
Hyperalgesia 1 74.96 Quite High
Diabetic Neuropathy 1 66.20 Quite High
Neuralgia 1 65.28 Quite High
Herpes Simplex Virus Infection 1 64.88 Quite High
Neuropathic Pain 14 60.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors.
Negative_regulation (inhibitors) of Cav2 associated with addiction and calcium channel
1) Confidence 0.42 Published 2008 Journal Assay Drug Dev Technol Section Title Doc Link 18471074 Disease Relevance 0.28 Pain Relevance 0.62
Although the Cav2 channel subtypes differ in their voltage dependence of inactivation, by adjusting pre-trigger potassium concentrations, the degree of steady-state inactivation can be more closely matched across Cav2 subtypes to assess molecular selectivity.
Negative_regulation (matched) of Cav2 associated with addiction
2) Confidence 0.42 Published 2008 Journal Assay Drug Dev Technol Section Abstract Doc Link 18471074 Disease Relevance 0 Pain Relevance 0.23
In vivo pharmacological results with Ziconotide strongly support the hypothesis that a systemic small molecule inhibitor of Cav2.2 should be useful for treating pain.
Negative_regulation (inhibitor) of Cav2 associated with pain and ziconotide
3) Confidence 0.26 Published 2008 Journal The Journal of General Physiology Section Body Doc Link PMC2346569 Disease Relevance 0.73 Pain Relevance 1.30
The study by von Pawel et al 1999 concludes that (intravenous) topotecan was at least as effective as CAV in the treatment of patients with recurrent small-cell lung cancer and resulted in improved control of several symptoms.


Negative_regulation (effective) of CAV in lung associated with vincristine and lung cancer
4) Confidence 0.14 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2931489 Disease Relevance 0.19 Pain Relevance 0.14
The testing of other trisubstituted purines showed a correlation between CaV2.2 inhibition and cyclin-dependent kinase affinity that broke down after determining that a chemically unrelated inhibitor, kenpaullone, was a poor CaV2.2 inhibitor, and a kinase inactive analog (dimethylamino-olomoucine; DMAO) was a strong inhibitor, which together support a kinase independent effect.
Negative_regulation (inhibitor) of CaV2
5) Confidence 0.07 Published 2008 Journal J. Neurochem. Section Abstract Doc Link 18221369 Disease Relevance 0 Pain Relevance 0.47

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox